$6.4 Billion Suit Claims Bristol-Myers Delayed Cancer Drug to Avoid Shareholder Payment
Bristol Myers Squibb Co. was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought in 2019. According to a complaint in Manhattan …